Endonovo Therapeutics, Inc. (ENDV)

USD 0.0

(14.29%)

Market Cap (In USD)

255 Thousand

Revenue (In USD)

140.24 Thousand

Net Income (In USD)

6.92 Million

Avg. Volume

1.15 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.0E-4-0.0134
PE
-
EPS
-
Beta Value
-0.629
ISIN
US29272H3003
CUSIP
29272H300
CIK
1528172
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alan Brian Collier
Employee Count
-
Website
https://www.endonovo.com
Ipo Date
2012-11-15
Details
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.